GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?

被引：22
|
作者：
Zweck, Elric [1 ,2 ,3 ]
Roden, Michael [1 ,2 ,4 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, D-40225 Dusseldorf, Germany
[2] German Ctr Diabet Res, Munich, Germany
[3] Heinrich Heine Univ, Fac Med, Div Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany
[4] Heinrich Heine Univ, Fac Med, Div Endocrinol & Diabetol, Dusseldorf, Germany
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2019年 / 7卷 / 02期
关键词：
D O I：
10.1016/S2213-8587(18)30351-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 90
页数：3
相关论文
共 50 条
  • [41] Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
    Raza, Fatima Ali
    Altaf, Rafiya
    Bashir, Talha
    Asghar, Fatima
    Altaf, Rabiya
    Tousif, Sohaib
    Goyal, Aman
    Mohammed, Aisha
    Mohammad, Mahnoor Faisal
    Anan, Mahfuza
    Ali, Sajjad
    MEDICINE, 2024, 103 (44)
  • [42] Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor
    Helmstaedter, Johanna
    Keppeler, Karin
    Kuester, Leonie
    Muenzel, Thomas
    Daiber, Andreas
    Steven, Sebastian
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 659 - 676
  • [43] Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications
    Zhang, Xinyu
    Cao, Chao
    Zheng, Fei
    Liu, Chang
    Tian, Xiuqing
    CARDIOVASCULAR DRUGS AND THERAPY, 2025,
  • [44] Effects of GLP-1 receptor agonists on neurological complications of diabetes
    Garcia-Casares, Natalia
    Gonzalez-Gonzalez, Guillermo
    de la Cruz-Cosme, Carlos
    Garzon-Maldonado, Francisco J.
    de Rojas-Leal, Carmen
    Ariza, Maria J.
    Narvaez, Manuel
    Barbancho, Miguel Angel
    Garcia-Arnes, Juan Antonio
    Tinahones, Francisco J.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2023, 24 (04): : 655 - 672
  • [45] Effects of GLP-1 receptor agonists on neurological complications of diabetes
    Natalia García-Casares
    Guillermo González-González
    Carlos de la Cruz-Cosme
    Francisco J Garzón-Maldonado
    Carmen de Rojas-Leal
    María J Ariza
    Manuel Narváez
    Miguel Ángel Barbancho
    Juan Antonio García-Arnés
    Francisco J. Tinahones
    Reviews in Endocrine and Metabolic Disorders, 2023, 24 : 655 - 672
  • [46] Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder
    Klausen, Mette Kruse
    Knudsen, Gitte Moos
    Vilsboll, Tina
    Fink-Jensen, Anders
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2025, 136 (03)
  • [47] GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?
    Muzurovic, Emir
    Yumuk, Volkan Demirhan
    Rizzo, Manfredi
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (12)
  • [48] Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods
    Sharma, Smriti
    Bhatia, Vinayak
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (08) : 1015 - 1024
  • [49] Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?
    Caruso, Paola
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Esposito, Katherine
    Giugliano, Dario
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2023, 39 (07)
  • [50] Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
    Seghieri, Marta
    Christensen, Alexander S.
    Andersen, Andreas
    Solini, Anna
    Knop, Filip K.
    Vilsboll, Tina
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
12345